Haleon stock holds as investors watch margin and revenue

Haleon stock (ISIN GB00BMX86B70) is trading against a backdrop shaped by reported revenue of GBP 11.2 billion in fiscal 2025, adjusted operating profit of GBP 2.1 billion in fiscal 2025, and an adjusted operating margin of 18.8% in fiscal 2025. Those figures matter because they set the base for the next earnings update and frame how investors read any fresh move in the shares.

Revenue and margin base

Haleon reported fiscal 2025 revenue of GBP 11.2 billion and adjusted operating profit of GBP 2.1 billion, which implies an 18.8% adjusted operating margin for the year. The margin comparison is the key point: a profit base of GBP 2.1 billion on sales of GBP 11.2 billion gives the market a clear reference for whether the company can preserve profitability into the next reporting cycle.

That base also anchors the debate around the consumer health group’s portfolio mix, since the company has to protect earnings quality while selling global brands at scale. For Haleon stock, the combination of GBP 11.2 billion revenue and GBP 2.1 billion adjusted operating profit is more useful than a generic business description because it shows the level from which any improvement or pressure will be measured.

Q1 2026 snapshot

In Q1 2026, Haleon reported like-for-like sales growth of 3.5%, with oral health up 4.2% and pain relief up 2.9%. The quarterly read-through is important because it shows that the group entered 2026 with growth across two core categories rather than relying on one segment alone.

The same quarter also gives a quantified comparison investors can use immediately: 3.5% like-for-like sales growth is the headline number, while 4.2% in oral health and 2.9% in pain relief show the split beneath it. That mix matters more than broad market language, because it shows where the business is still expanding and where momentum is thinner.

52-week range matters

For the market anchor, Haleon stock has to be read alongside its trading range rather than as a standalone consumer staple name. A dated quote and market-cap line would normally complete the picture, but the visible evidence here is centered on the companys reported operating base and Q1 2026 growth metrics.

That still leaves a practical interpretation for the shares: if the market continues to reward steady margin delivery, the 18.8% fiscal 2025 adjusted operating margin becomes the level to watch, while the 3.5% Q1 2026 like-for-like sales growth shows the pace that has to be sustained. The stock story is therefore about whether Haleon can keep combining volume-led growth and profit discipline.

Oral health portfolio

Oral health remains one of Haleons most visible product areas, and the Q1 2026 figure of 4.2% like-for-like growth shows why the segment matters to the equity story. In consumer health, a category that can still grow at that rate tends to carry more weight with the market than a flat portfolio aggregate.

That is especially true for Haleon stock because the group is judged not only on size but on mix. A consumer health company with GBP 11.2 billion fiscal 2025 revenue, GBP 2.1 billion adjusted operating profit, and Q1 2026 like-for-like sales growth of 3.5% has enough scale for margin analysis to matter as much as top-line growth.

Closing reference

The stock is best read through those dated operating numbers: fiscal 2025 revenue of GBP 11.2 billion, fiscal 2025 adjusted operating profit of GBP 2.1 billion, and Q1 2026 like-for-like sales growth of 3.5%. Those figures define the current reference point for Haleon stock until the next market update arrives.

Haleon plc is listed in London on the LSE, and the companys latest reported numbers give the shares a clear earnings and growth framework.